Affinivax is a biotechnology company developing a next generation approach in vaccine technologies with the goal of designing vaccines that provide broad protection against challenging diseases afflicting children and adults in both the developing and developed worlds.
This novel and highly efficient vaccine technology – named MAPS for Multiple Antigen Presenting System – enables the high affinity binding of protective polysaccharides and proteins in a single vaccine and uniquely induces a broad and protective immune response. The final MAPS complex has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today.
The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform. Learn More about our Collaborators>
The vision of Affinivax is to offer life-saving vaccines targeting the most challenging diseases and provide the broadest disease protection for people of all ages across the globe.